Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.

Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.